TREATMENT WITH BARICITINIB INMODERATE AND SEVERE COVID-19 PATIENTS
PDF

Categories

How to Cite

Vashakidze, E., Megrelishvili, T., Mikadze, I., Pachkoria, E., & Jangavadze, M. (2021). TREATMENT WITH BARICITINIB INMODERATE AND SEVERE COVID-19 PATIENTS. Collection of Scientific Works of Tbilisi State Medical University, 55, 69–70. https://doi.org/10.52340/csw.2021.55.01

Abstract

A novel coronaviral infection which was first discoveredin China in December 2019 rapidly spread around the worldand caused a pandemic. Reducing the lethality in hospital-ized patients is a major medical issue since the onset of pan-demic. Baricitinib is used in covid-19 patients with pneumo-nia at TSMU First University Clinic. From 70 patients 38(54.8%) were female and 32 (45.2) male. 62 (88.6%) patientswere from therapeutic unit and 8 (11.4%) patients from inten-sive care unit. Baricitinib was prescribed 4 mg oncedaily incombination with standard treatment. Patients in the thera-peutic unit were prescribed Baricitinib on the 6th-8th day afterthe onset of symptoms, and in patients in the intensive careunit on the 12th-16th day after the onset of symptoms. Barici-tinib was prescribed with hormonotherapy (Dexamethasone).From 8 (11.4%) intensive care unit patients who take Barici-tinib on the 12th-16th day after the onset of symptoms, 7 (10%)required invasive mechanical ventilation and 6 cases endedlethally. Thus, the maximum effectiveness of baricitinib isseen on the 5th-8th day after the onset of the clinical sings,while Baricitinib does not affect on the course and outcomeof disease when it prescribed in the later, oxygenation defi-ciency phase.      
https://doi.org/10.52340/csw.2021.55.01
PDF

References

HorbyP . Lim WS .EmbersonJR . Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021; 384: 693-704.

U.S. Food & Drug Administration . FDA combating COVID-19 with therapeutics; 2021. https://www.fda.gov/media/136832/download. Accessed April 25, 2021.

Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795-807.

Stebbing J, Sánchez-Nievas G, Falcone M, et al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv. 2020;7:eabe4724.

Stebbing J, Krishnan V, de Bono S, et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020; 12:e12697.

Cantini F, Niccoli L, Nannini C, et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicenter study. J Infect. 2020;81:647-649.

Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130:6409-6416.

Downloads

Download data is not yet available.

Metrics

No metrics found.